Brightening the Future of Immunology with New Frontiers in Science

We are driven by a shared vision of a future in which immune-mediated diseases no longer hold patients and their loved ones back.

Unlocking hope

Address significant unmet medicals needs in immunology

With over 20 years of research under our belt, we have built a vast proprietary knowledge of disease biology.

The challenge is to modulate the immune system without compromising your own ability to fight infection and disease. We see an opportunity to improve the standard of care.

Pioneering for patients

High unmet need for immune-mediated diseases

4 million people

worldwide are affected by immune-mediated diseases1

80 types

of immune-mediated diseases

Immune system

mistakenly attacks healthy cells and tissues

1 World Health Organization. (2020). Global Report on Immune-Mediated Diseases.

Our focus in immunology

Striving to deliver targeted treatments for immune-mediated diseases

Multiple modes-of-action

JAK Program

Development of medicines to target Janus kinases (JAKs) to address the chronic inflammation.

TYK Program

Development of precise medicines that target specific elements of the immune system, distinguishing them from current therapies that broadly suppress the immune system.

SIK Program

Development of new medicines that inhibit SIK proteins to restore immune balance in immune-mediated diseases, which is different from existing therapies that mainly suppress the immune system.

CAR-T Program

Scientists are exploring how CAR-T therapy can play a role in the treatment of immune-mediated diseases.

Daniele D’Ambrosio

Head of Immunology

We are driven by the belief that even a small step towards better treatment for immune-mediated diseases can make a huge difference in the lives of patients and their loved ones. It is this unwavering passion that inspires us to push beyond the boundaries of conventional thinking and explore new frontiers in medicine.


Our commitment in immunology

Do you need everything in one place about our efforts in brightening the future of immunology?

Multiple drug modalities

Rapidly advancing and expanding our immunology pipeline

We are more passionate than ever about rapidly advancing and expanding our immunology pipeline, and want to brighten the horizon of possibilities with multiple modes-of-action and drug modalities.

We are evaluating CAR-T therapy for the treatment of refractory systemic lupus erythematosus and other chronic immune-mediated diseases to expand our cell therapy portfolio.

Disease areas

More about our work in Oncology

We are united around our mission to redefine the future of cancer treatment. Our goal is to help people facing cancer live longer, better lives.


Work with us!

We are adding new capabilities, technologies and product candidates through internal and external innovation. Let’s start #PioneeringForPatients, together!

Galapagos Health

Explore our HCP Portal

Are you a healthcare professional? Are you looking for Galapagos’ medical education, product information or congress presence? Look no further!